NICE Secures Breakthrough HTA Decision for Prostate Cancer
NICE issues breakthrough HTA decision on Bayer’s prostate cancer therapy.
Speciality
NICE accelerates breakthrough framework for complex liver diseases
NICE drives innovation, reshaping MASH evaluations with transformative guidance.
Novartis secures triumphant $12 billion takeover of Avidity
The billion-dollar acquisition advances Avidity’s RNA platform with momentum.
J&J Launches AI in Surgery Funding via Polyphonic™ Fund
J&J invests $100M in AI in surgery funding to drive smarter surgical solutions.
Stryker’s Incompass Total Ankle Wins FDA Clearance
Stryker FDA-cleared InCompass Ankle; protein degrader partnerships drive innovation.
Judge Rules ReWalk Device Is Medically Necessary for Medicare
Medicare exoskeleton coverage approved for ReWalk Personal Exoskeleton, sets key precedent.
Vor Bio and RemeGen Seal $4B Global License Agreement
Vor Bio, RemeGen sign Global License Agreement for RC98 development.
Novartis Inks $750M Flagship Pact for Cardio Innovation
Novartis makes a $750M flagship pact to address cardiovascular disease innovation.
Gilead Taps Kymera in $750M Oncology Deal to Harness Molecular Glue Degraders
Gilead and Kymera seal a $750M deal for innovative CDK2 molecular glue degraders in oncology.
Neuron23’s NEU-411 Trial Shifts the Parkinson’s Paradigm Toward Precision
Neuron23 advances NEU-411 into Phase II Parkinson’s trial, driven by biomarker-based strategies and strong investor support.